
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2638328/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Correction for Rando et al., "Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure― MSystems, 2022, , e0144721.	3.8	2
2	Differential COVID-19 Symptoms Given Pandemic Locations, Time, and Comorbidities During the Early Pandemic. Frontiers in Medicine, 2022, 9, 770031.	2.6	10
3	Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine. Frontiers in Pharmacology, 2022, 13, 812338.	3.5	3
4	Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities. European Heart Journal, 2021, 42, 697-699.	2.2	4
5	ST-segment elevation in patients presenting with COVID-19: case series. European Heart Journal - Case Reports, 2021, 5, ytaa553.	0.6	12
6	Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans. Annals of Internal Medicine, 2021, 174, 289-297.	3.9	79
7	Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles, 2021, 10, e12093.	12.2	182
8	Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study. Frontiers in Pharmacology, 2021, 12, 700776.	3.5	4
9	Separation, characterization, and standardization of extracellular vesicles for drug delivery applications. Advanced Drug Delivery Reviews, 2021, 174, 348-368.	13.7	66
10	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Network Open, 2021, 4, e2116901.	5.9	179
11	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. MSystems, 2021, 6, e0009521.	3.8	26
12	Total and Out-of-Pocket Expenditures on Antihypertensive Medications in the United States, 2007–2019. Hypertension, 2021, 78, 1662-1664.	2.7	0
13	Identification and Development of Therapeutics for COVID-19. MSystems, 2021, 6, e0023321.	3.8	20
14	24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency. Frontiers in Endocrinology, 2021, 12, 751191.	3.5	10
15	Characterizing Long COVID: Deep Phenotype of a Complex Condition. EBioMedicine, 2021, 74, 103722.	6.1	127
16	Primary Aldosteronism. JACC: Cardiovascular Imaging, 2020, 13, 2160-2161.	5.3	2
17	Responsible, practical genomic data sharing that accelerates research. Nature Reviews Genetics, 2020, 21, 615-629.	16.3	66
18	Extracellular Vesicles in Essential Hypertension: Hidden Messengers. Current Hypertension Reports, 2020, 22, 76.	3.5	12

#	Article	IF	CITATIONS
19	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE) Tj ETQq1	1 0.784314 2.0	4 rgBT /Over
20	Rigor before speculation in COVID-19 therapy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1027-L1028.	2.9	3
21	Managing hypertension during the COVID-19 pandemic. Journal of Human Hypertension, 2020, 34, 415-417.	2.2	19
22	Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19― Circulation Research, 2020, 126, e140-e141.	4.5	11
23	Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls. Current Hypertension Reports, 2020, 22, 20.	3.5	10
24	Pandemic Pandemonium. Circulation, 2020, 141, 2045-2047.	1.6	15
25	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	4.5	74
26	Pharmacologic treatment of hypertension. , 2019, , 477-482.		3
27	Privacy-Preserving Generative Deep Neural Networks Support Clinical Data Sharing. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005122.	2.2	172
28	Current Status of Angiotensin Receptor Blocker Recalls. Hypertension, 2019, 74, 1275-1278.	2.7	12
29	Medicare reimbursement policy for ambulatory blood pressure monitoring: A qualitative analysis of public comments to the Centers for Medicare and Medicaid Services. Journal of Clinical Hypertension, 2019, 21, 1803-1809.	2.0	6
30	For what factors should we normalize urinary extracellular mRNA biomarkers?. Biomolecular Detection and Quantification, 2019, 17, 100090.	7.0	16
31	Hypertension Hot Potato — Anatomy of the Angiotensin-Receptor Blocker Recalls. New England Journal of Medicine, 2019, 380, 1589-1591.	27.0	37
32	Strengthening a societal tie and other new initiatives for 2019. Journal of Human Hypertension, 2019, 33, 173-173.	2.2	0
33	Personalized Medicine and the Treatment of Hypertension. Current Hypertension Reports, 2019, 21, 13.	3.5	28
34	Score one for the clinical trial data sharing experiment. European Journal of Preventive Cardiology, 2019, 26, 567-568.	1.8	1
35	Hypertension. Annals of Internal Medicine, 2019, 170, ITC65.	3.9	10
36	Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 487-492.	3.6	40

#	Article	IF	CITATIONS
37	Opening Opportunities With Open Data. JACC: Heart Failure, 2018, 6, 530-532.	4.1	1
38	Use of physicianâ€recommended nonâ€pharmacological strategies for hypertension control among hypertensive patients. Journal of Clinical Hypertension, 2018, 20, 518-527.	2.0	15
39	Reach Out Churches: A Community-Based Participatory Research Pilot Trial to Assess the Feasibility of a Mobile Health Technology Intervention to Reduce Blood Pressure Among African Americans. Health Promotion Practice, 2018, 19, 495-505.	1.6	32
40	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	12.2	6,961
41	Human Urinary mRNA as a Biomarker of Cardiovascular Disease. Circulation Genomic and Precision Medicine, 2018, 11, e002213.	3.6	25
42	Monitoring Blood Pressure Outside of the Doctor's Office. JAMA - Journal of the American Medical Association, 2018, 320, 1830.	7.4	4
43	Out-of-Office Blood Pressure Monitoring in 2018. JAMA - Journal of the American Medical Association, 2018, 320, 1805.	7.4	12
44	Clinical research using extracellular vesicles: insights from the International Society for Extracellular Vesicles 2018 Annual Meeting. Journal of Extracellular Vesicles, 2018, 7, 1535744.	12.2	23
45	Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017. Journal of Extracellular Vesicles, 2018, 7, 1473707.	12.2	60
46	Alternative Approaches for Lowering Blood Pressure. , 2018, , 274-279.		0
47	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. European Heart Journal, 2018, 39, 3128-3134.	2.2	30
48	Primary Aldosteronism. Circulation, 2018, 138, 823-835.	1.6	113
49	EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nature Methods, 2017, 14, 228-232.	19.0	886
50	Cigarette Smoking and Subtypes of Uncontrolled Blood Pressure Among Diagnosed Hypertensive Patients: Paradoxical Associations and Implications. American Journal of Hypertension, 2017, 30, 602-609.	2.0	21
51	Data-Sharing Models. New England Journal of Medicine, 2017, 376, 2305-2306.	27.0	11
52	Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clinical Endocrinology, 2017, 87, 665-672.	2.4	68
53	Primary Aldosteronism in the Primary Care Clinic: Rife or Rare?. Endocrine Practice, 2016, 22, 1350-1352.	2.1	Ο
54	Personalized medicine and treatment approaches in hypertension: current perspectives. Integrated Blood Pressure Control, 2016, 9, 59.	1.2	18

#	Article	IF	CITATIONS
55	Acute increase in blood pressure during inhalation of coarse particulate matter air pollution from an urban location. Journal of the American Society of Hypertension, 2016, 10, 133-139.e4.	2.3	40
56	Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. Journal of Investigative Medicine, 2015, 63, 862-866.	1.6	7
57	Arm Position During Ambulatory Blood Pressure Monitoring: A Review of the Evidence and Clinical Guidelines. Journal of Clinical Hypertension, 2014, 16, 225-230.	2.0	8
58	A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. Journal of Human Hypertension, 2014, 28, 3-9.	2.2	22
59	Anxiety in the "Age of Hypertension― Current Hypertension Reports, 2014, 16, 486.	3.5	23
60	The Contribution of the ACCOMPLISH Trial to the Treatment of Stage 2 Hypertension. Current Hypertension Reports, 2014, 16, 419.	3.5	5
61	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	27.0	1,848
62	Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: Insights from the Veterans Affairs CART Program. American Heart Journal, 2014, 168, 340-345.	2.7	5
63	Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 468-473.e4.	3.8	9
64	Data quality of an electronic health record tool to support VA cardiac catheterization laboratory quality improvement: The VA Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART) program. American Heart Journal, 2013, 165, 434-440.	2.7	97
65	Pericardial Effusion in Renal Disease: To Tap or Not to Tap. Cardiology, 2011, 120, 204-208.	1.4	3
66	Combination therapy as initial treatment for newly diagnosed hypertension. American Heart Journal, 2011, 162, 340-346.	2.7	47
67	The possibility of unmeasured confounding variables in observational studies: a forgotten fact?. Heart, 2011, 97, 1815-1816.	2.9	4
68	Association of angiotensinâ€converting enzyme inhibitorâ€associated angioedema with transplant and immunosuppressant use. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1381-1387.	5.7	39
69	Les effets secondaires aigus des inhibiteurs de l'enzyme de conversion de l'angiotensine dont l'angioÅ"dÃïme, diffA©rents dans leur étiologie clinique, partagent une physiopathologie semblable. Revue Francaise D'allergologie Et D'immunologie Clinique, 2008, 48, 434-440.	0.1	1
70	Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. Hypertension, 2008, 51, 141-147.	2.7	128
71	Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition. Hypertension, 2008, 51, 454-459.	2.7	38
72	Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema. Journal of Allergy and Clinical Immunology, 2007, 120, 403-408.	2.9	48

#	Article	IF	CITATIONS
73	Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Immunology and Allergy Clinics of North America, 2006, 26, 725-737.	1.9	135